Want to see SRTA full AI Analyst Report?
SRTA Stock Chart & Stats
$4.57
--
Market closed
$4.57
--
Day’s Range― - ―
52-Week Range$3.57 - $6.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.20M
Market Cap
$468.11M
Enterprise Value$446.73M
Total Cash (Recent Filing)$58.79M
Total Debt (Recent Filing)$4.47M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Aug 11, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding86,526,570
10 Day Avg. Volume1,519,011
30 Day Avg. Volume1,202,214
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue1.76
Enterprise Value/Gross Profit8.10
Enterprise Value/Ebitda-33.82
Forecast
1Y Price Target
$9.75Price Target Upside113.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$272.93M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a sizable equity base provide durable financial flexibility, cushioning against operating cash burn and funding near-term growth or M&A without immediate refinancing. This downside protection supports multi-quarter execution and capital allocation optionality.
Profitability TurnaroundA sustained swing to positive net income and materially improved ROE signal that the company can deliver bottom-line results, which enhances internal funding capacity and investor confidence. If maintained, this earnings base aids reinvestment and reduces reliance on external capital.
Clinical Business MomentumRapid clinical revenue growth and higher clinical gross margins reflect successful product/service adoption and cross-sell traction. Structural tailwinds (greater NRP adoption and third-party surgical recovery) underpin durable demand for integrated clinical-logistics services and support margin expansion over time.
Bears Say
Persistent Negative Cash FlowMaterial and persistent operating and free cash flow deficits create dependence on balance-sheet liquidity, earn-outs, or external financing. Over multiple quarters this elevates funding risk, constrains reinvestment, and increases the chance that capital raises dilute stakeholders or limit strategic optionality.
Core Operating LossesProfitability driven by non-operating items or one-offs reduces earnings quality. Continued negative operating profit implies core business economics are unproven; if operating losses persist, reported net income may prove volatile and less repeatable, challenging long-term margin sustainability.
Logistics Margin VolatilityLogistics margins are sensitive to customer mix, trip lengths and operational disruptions (weather, airport closures), producing quarter-to-quarter variability. Structural margin volatility complicates forecasting, weakens predictability of consolidated margins, and makes scaling returns harder to lock in.
Strata Critical Medical News
SRTA FAQ
What was Strata Critical Medical, Inc.’s price range in the past 12 months?
Strata Critical Medical, Inc. lowest stock price was $3.57 and its highest was $6.50 in the past 12 months.
What is Strata Critical Medical, Inc.’s market cap?
Strata Critical Medical, Inc.’s market cap is $468.11M.
When is Strata Critical Medical, Inc.’s upcoming earnings report date?
Strata Critical Medical, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.
How were Strata Critical Medical, Inc.’s earnings last quarter?
Strata Critical Medical, Inc. released its earnings results on May 06, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.038 by $0.068.
Is Strata Critical Medical, Inc. overvalued?
According to Wall Street analysts Strata Critical Medical, Inc.’s price is currently Undervalued.
Does Strata Critical Medical, Inc. pay dividends?
Strata Critical Medical, Inc. does not currently pay dividends.
What is Strata Critical Medical, Inc.’s EPS estimate?
Strata Critical Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Strata Critical Medical, Inc. have?
Strata Critical Medical, Inc. has 86,526,570 shares outstanding.
What happened to Strata Critical Medical, Inc.’s price movement after its last earnings report?
Strata Critical Medical, Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.038. Following the earnings report the stock price went up 10.581%.
Which hedge fund is a major shareholder of Strata Critical Medical, Inc.?
Currently, no hedge funds are holding shares in SRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Strata Critical Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.75 (113.35% Upside)
$9.75 (113.35% Upside)
Blogger Sentiment
Neutral
SRTA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $420.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.99%
12-Months-Change
Fundamentals
Return on Equity
18.97%
Trailing 12-Months
Asset Growth
30.76%
Trailing 12-Months
Company Description
Strata Critical Medical, Inc.
Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.
SRTA Company Deck
SRTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive tone driven by very strong year-over-year revenue (+87.4%), doubled gross profit, rapid build-out and commercial traction in the Clinical business, healthy cash on hand and an active M&A pipeline. Offsetting these positives were sequential softness in Logistics revenue and margins (customer mix and weather-related disruptions), a sequential decline in adjusted EBITDA margin, some one-time cash timing effects, and ongoing uncertainty in donor volumes. Management reiterated full-year guidance and highlighted balance sheet capacity, suggesting confidence in execution despite near-term noise.View all SRTA earnings summariesSRTA Stock 12 Month Forecast
Average Price Target
$9.75
▲(113.35% Upside)
Technical Analysis
Ownership Overview
14.91% Insiders
12.45% Mutual Funds
38.49% Other Institutional Investors
22.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---